- Home
- CARS vs ESPR Comparison
CARS vs ESPR Comparison
Compare CARS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- ESPR
- Stock Information
- Founded
- CARS 1998
- ESPR 2008
- Country
- CARS United States
- ESPR United States
- Employees
- CARS N/A
- ESPR N/A
- Industry
- CARS Motor Vehicles
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- ESPR Health Care
- Exchange
- CARS Nasdaq
- ESPR Nasdaq
- Market Cap
- CARS 692.6M
- ESPR 660.1M
- IPO Year
- CARS 2017
- ESPR 2013
- Fundamental
- Price
- CARS $11.42
- ESPR $2.93
- Analyst Decision
- CARS Strong Buy
- ESPR Buy
- Analyst Count
- CARS 5
- ESPR 6
- Target Price
- CARS $17.90
- ESPR $6.50
- AVG Volume (30 Days)
- CARS 943.9K
- ESPR 6.0M
- Earning Date
- CARS 11-06-2025
- ESPR 11-06-2025
- Dividend Yield
- CARS N/A
- ESPR N/A
- EPS Growth
- CARS N/A
- ESPR N/A
- EPS
- CARS 0.47
- ESPR N/A
- Revenue
- CARS $719,767,000.00
- ESPR $303,802,000.00
- Revenue This Year
- CARS $2.52
- ESPR $18.83
- Revenue Next Year
- CARS $3.00
- ESPR N/A
- P/E Ratio
- CARS $24.32
- ESPR N/A
- Revenue Growth
- CARS 0.20
- ESPR 2.83
- 52 Week Low
- CARS $9.56
- ESPR $0.69
- 52 Week High
- CARS $20.47
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CARS 52.17
- ESPR 53.73
- Support Level
- CARS $11.12
- ESPR $2.42
- Resistance Level
- CARS $11.75
- ESPR $3.26
- Average True Range (ATR)
- CARS 0.49
- ESPR 0.21
- MACD
- CARS 0.15
- ESPR 0.00
- Stochastic Oscillator
- CARS 56.99
- ESPR 60.07
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.